You are here: Industry Insights > VLA2001

News List

Valneva Begins COVID Vax Production to Optimize Potential Deliveries contractpharma
January 29, 2021
Valneva SE began production of its inactivated, adjuvanted COVID-19 vaccine candidate in parallel to the ongoing clinical studies, in an effort to optimize the timeline for potential deliveries of the vaccine.
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate worldpharmanews
January 14, 2021
Valneva SE, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its ...
Valneva initiates Phase 1/2 clinical study of inactivated, adjuvanted COVID-19 vaccine candidate worldpharmanews
December 17, 2020
Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva inks €1.37bn Covid-19 vaccine supply deal with UK pharmaceutical-technology
September 16, 2020
Speciality vaccines developer Valneva has announced a partnership worth €1.37bn with the UK Government to supply its inactivated Covid-19 vaccine candidate, VLA2001.
Valneva, Dynavax Enter COVID-19 Vax Supply Pact contractpharma
September 16, 2020
Dynavax will supply CpG 1018 to produce up to 100 million doses of VLA2001 vaccine in 2021.
Valneva to Provide SARS-CoV-2 Vax Candidate to UK Govt contractpharma
July 21, 2020
Valneva's VLA2001, an inactivated whole virus vaccine candidate against coronavirus is expected to enter clinical studies by the end of 2020.

Previous page 1 2 3 Next page